Upregulation of p-AKT might enhance tumor progression and mediate resistance to drugs (Liu R. et al., 2020), and it has been well known that the binding of ligand to a transmembrane receptor, receptor tyrosine kinase (RTK), activates both PI3K/AKT and MAPK pathways to promote cell survival (Cao et al., 2019). This evidence concerns the gene NRP1 and neoplasm.